Anaemia is prevalent among critically ill patients, and 20-40% receive red blood cell (RBC) transfusions [1] . Evidence shows us that for most patients, restrictive (RBC) transfusion represents best practice [2] . One reason for this is that we increasingly recognise that RBCs might have harmful as well as beneficial effects. Understanding the risk-benefit balance between tolerating anaemia and treating it with RBCs remains a key question in healthcare. Changes that occur during RBC storage are a potential key modifier of this risk-benefit balance.
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After donation, RBCs can be stored for 35-42 days. To minimise wastage, blood banks typically issue the oldest units first and the average transfused storage age is 18-21 days in most blood services. The permitted storage duration is mainly defined by demonstrating 75% recovery of transfused RBCs in the recipient circulation 24 h post-transfusion [3] , but this measures survival of RBCs and not whether they can carry oxygen to tissues (which is why clinicians give them). During storage, a plethora of structural and biochemical changes occur which, from a pathophysiological perspective, decrease oxygen carrying capacity and might be harmful (Fig. 1) . Stored RBCs may modulate host immune response and impair microcirculatory flow [4, 5] , both clearly detrimental during critical illness. Numerous observational cohort studies have explored the association between RBC storage and a range of outcomes, both in critical illness and other populations [6] . The findings are heterogeneous, with many suggesting harm from older RBCs, but this research is subject to major confounding and in isolation should not change practice. The organisational and financial implications of supplying fresher RBCs are enormous and require high quality evidence. Storage time is not the only potential influence on the risk-benefit balance from RBC transfusion. Donor characteristics such as age and gender have also been associated with recipient outcomes [7] , and the manufacturing processes itself (such as the storage medium) may influence RBC properties when transfused [8] .
It is remarkable that until 2015 we had no randomised controlled trials (RCTs) including more than 100 patients addressing the question of storage lesion, but this has changed during the past 3 years.
In this issue of Intensive Care Medicine, Rygard et al. present a systematic review and meta-analysis of trials comparing shorter versus longer RBC storage time in adult critical care [9] , including the TRANSFUSE trial, published very recently. This high quality review conforms closely to Cochrane and PRISMA guidance. The primary outcomes of interest were mortality, adverse events and post-transfusion infections; observational studies have suggested that all of these may be increased by transfusing older RBCs. In additional to estimating overall effect sizes, the authors used a technique called trial sequential analysis (TSA), which quantifies the statistical reliability of data in a cumulative meta-analysis. This technique protects against spurious type I or II error, and allows an estimation of how conclusive evidence is for pre-specified effect sizes. The authors included seven trials in 18,283 patients. Almost all patients were in three large RCTs: ABLE (N = 2510), INFORM (N = 10,578), and TRANSFUSE (N = 4994). Importantly, all trials used leucodepleted RBCs and in the two trials judged at lowest risk of bias (ABLE and TRANSFUSE) the mean pre-transfusion haemoglobin was 76-77 g/L indicating evidence-based restrictive practice. ABLE and TRANSFUSE were also double-blind trials, and had very complete follow-up. The trials compared a fresher (6-11 days) with an older (21-24 days) RBC group. The older groups represented 'usual practice' in most healthcare systems, but it is relevant that few patients received RBCs aged more than 30 days when storage changes are most severe. Patients received a mean of four units during ICU stay.
The authors observed no effects from fresher RBCs on mortality, adverse effects or post-transfusion infections in the overall analysis or when restricted to the ABLE and TRANSFUSE trials. Of relevance, statistical heterogeneity for mortality was low indicating consistent findings. The pooled effect size indicated a risk ratio of 1.04 (confidence intervals 0.98-1.10). These point estimates favour older blood and statistically exclude a greater than 2% benefit from fresher RBCs. The alternative TSA approach concluded that a 10% relative increase/decrease in relative risk of death from fresher RBCs could be excluded by these data. As mortality was 36% in ABLE and 24% in TRANSFUSE, this suggests that effects greater than 3.6% are highly unlikely. Although statistical certainty for adverse events and post-operative infections was lower, the non-significant point estimates also favoured older RBCs.
We have rarely had such certainty regarding a common critical care intervention. This study provides confidence that requesting fresher RBCs confers no outcome benefit for our patients, and we should not change our current practice. The point estimate favouring standard age RBCs is thought-provoking and it is notable that recent observational research, despite its clear limitations, has also shown associations between fresh blood and worse Fig. 1 Some of the physical and biochemical changes associated with red blood cell storage outcomes [10] . These trials also do not reassure us that the oldest RBCs are as safe as usual care although a secondary analysis of the INFORM trial found no difference for 'oldest' versus 'freshest' subgroups, which is reassuring. As blood banks usually issue RBCs before these older storage times this is also less clinically relevant. We also cannot be sure about effects during major haemorrhage, where RBC dose is high and should be cautious assuming these data apply when pre-storage leucodepletion is not standard practice.
In summary, Rygard and colleagues helpfully summarise the substantially increased knowledge regarding clinical effects from RBC storage from the past 3 years, and definitively show that fresh RBCs are neither necessary nor justified during critical illness. There is, however, more research to do for this fundamental healthcare intervention, for example in relation to the importance of donor factors and the way we process RBCs.
